NCT00284193View on ClinicalTrials.gov

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2009

Conditions
Hemophilia A
Interventions
DRUG

rFVIIa-FEIBA therapy for hemophilia A inhibitors

DOses tailored per ex vivo spiking thrombin generation

DRUG

FEIBA- Activated Prothrombin Complexes

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT00284193 - Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII | Biotech Hunter | Biotech Hunter